- Exagen Inc. (XGN, Financial) will announce its Q1 2025 financial results on May 5, 2025.
- The company will host a conference call to discuss the results at 8:30 a.m. ET.
- A replay of the call will be available until May 19, 2025.
Exagen Inc. (XGN), a leading provider of autoimmune testing solutions, is slated to release its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the market opens. This announcement will provide insights into the company’s financial performance for the quarter ending March 31, 2025.
Following the release, Exagen's President and CEO John Aballi, alongside CFO Jeff Black, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) to review the results and discuss the company’s business strategies and outlook. Interested investors and analysts can participate in the call by dialing 201-389-0918 if within the U.S. or +1-877-407-0890 for international callers. Additionally, a live webcast will be accessible on the Exagen investor relations website.
For those unable to attend the live session, a replay of the conference call will be available until May 19, 2025. Participants can access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using the passcode 13753132. The webcast replay will also be available on the Exagen investor relations website approximately one hour after the call concludes.
Exagen Inc. continues to leverage its diagnostics expertise to advance the understanding and treatment of autoimmune diseases through innovative testing solutions like AVISE® CTD, which aids in the diagnosis of complex conditions, enhancing clinical outcomes for patients worldwide.
